SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
January 21 2021 - 4:05PM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced
that its SYMJEPI® (epinephrine) Injection products are now
available to members of the Walgreens Prescription Savings Club
program, for a discounted price of $99.99 for a two-pack, the
lowest price offered for epinephrine products through the Walgreens
Prescriptions Savings Club, and the lowest price for epinephrine
devices on the market1.
At the start of 2021, Adamis’ SYMJEPI 0.3mg and
SYMJEPI 0.15mg Injection products, which are used in the emergency
treatment of acute allergic reactions, were added to the Walgreens
Prescription Savings Club program. The Walgreens Prescription
Savings Club offers customers, who pay an annual membership fee,
significant savings off retail prices on thousands of medications.
For full details visit
www.walgreens.com/psc/prescription-savings-club.
Dr. Dennis J. Carlo, President and Chief
Executive Officer of Adamis Pharmaceuticals, added, “We are
very excited Walgreens has added SYMJEPI through its Prescription
Savings Club and feel this program will avail this potentially
life-saving medication to the patients that need it most. Adamis
remains committed to making SYMJEPI the most affordable epinephrine
product available to patients.”
Important Safety Information
ContraindicationsNone.
Warnings and Precautions
- You should get emergency medical care
right away after using SYMJEPI.
- You may need to use a second SYMJEPI
(epinephrine) injection if symptoms continue or recur. Only a
healthcare provider should give additional doses of epinephrine if
you need more than 2 injections for a single anaphylaxis
episode.
- SYMJEPI should only be
injected into the middle of your outer thigh (upper leg)
with the needle facing downwards. Never inject into any
other part of the body. If you accidentally inject SYMJEPI
into any other part of your body, go to the nearest emergency room
right away. Tell the healthcare provider where on your body you
received the accidental injection. SYMJEPI can be injected
through your clothing if needed.
- The needle cap on the SYMJEPI
prefilled syringe helps to prevent needle sticks and accidental
injection of epinephrine. Do not remove the needle cap until you
are ready to use it.
- Never put your thumb, fingers,
or hand over the exposed needle.
- If an accidental injection
happens, get medical help right away.
- Do not drop the carrier case or
SYMJEPI prefilled syringe. If the carrier case or prefilled syringe
is dropped, check for damage and leakage. Dispose of the prefilled
syringe and carrier case, and replace if damage or leakage is
noticed or suspected.
- Do not place patient information or
any other foreign objects in the carrier case with the prefilled
syringe, as this may prevent you from removing the prefilled
syringe for use.
- If you inject a young child with
SYMJEPI, hold their leg firmly in place before and during the
injection to prevent injuries. Ask your healthcare provider to show
you how to properly hold the leg of a young child during
injection.
- Before using SYMJEPI, tell your healthcare provider about all
of your medical conditions, including if you:
- have heart problems or high blood pressure.
- have diabetes.
- have thyroid problems.
- have asthma.
- have a history of depression.
- have Parkinson’s disease.
- are pregnant or plan to become pregnant. It is not known if
epinephrine will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if
epinephrine passes into your breast milk.
Adverse ReactionsSYMJEPI may cause
serious side effects.
- Rarely, patients who have used
SYMJEPI may develop infections at the injection site within a few
days of an injection. Some of these infections can be
serious. Call your healthcare provider right away if you have any
of the following at an injection site:
- redness that does not go away
- swelling
- tenderness
- the area feels warm to the touch
- Cuts on the skin, bent needles, and
needles that remain in the skin after the injection, have happened
in young children who do not cooperate and kick or move during the
injection.
- If you have certain medical
conditions, or take certain medicines, your condition may get worse
or you may have longer lasting side effects when you use your
SYMJEPI. Talk to your healthcare provider about all your medical
conditions.
Common side effects of SYMJEPI include:
- fast, irregular or “pounding” heartbeat
- sweating
- headache
- weakness
- shakiness
- paleness
- feelings of over excitement, nervousness or anxiety
- dizziness
- nausea and vomiting
- breathing problems
These side effects may go away with rest. Tell your
healthcare provider if you have any side effect that bothers you or
that does not go away. These are not all the possible side effects
of SYMJEPI. For more information, ask your healthcare provider or
pharmacist.
Drug Interactions
- Tell your healthcare provider about
all the medicines you take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements.
- Tell your healthcare provider of all
known allergies.
- Especially tell your healthcare
provider if you take certain asthma medicines.
- SYMJEPI and other medicines may affect
each other, causing side effects. SYMJEPI may affect the way other
medicines work, and other medicines may affect how SYMJEPI
works.
- Know the medicines you take. Keep a
list of them to show your healthcare provider and pharmacist when
you get a new medicine.
Please see full
Prescribing Information for
SYMJEPI.
To report SUSPECTED ADVERSE REACTIONS,
contact Adamis Pharmaceuticals Corporation at 1-800-230-3935 or FDA
at 1-800-FDA-1088 or
www.fda.gov/medwatch.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a
specialty biopharmaceutical company primarily focused on developing
and commercializing products in various therapeutic areas,
including allergy, opioid overdose, respiratory and inflammatory
disease. The company’s SYMJEPI (epinephrine) Injection products are
approved by the FDA for use in the emergency treatment of acute
allergic reactions, including anaphylaxis. In addition to its
ZIMHI, naloxone injection product candidate, Adamis is developing
additional products, including treatments for acute respiratory
diseases, such as COVID-19, influenza, asthma and COPD. The
company’s subsidiary, U.S. Compounding, Inc., compounds
sterile prescription drugs, and certain nonsterile drugs for human
and veterinary use by hospitals, clinics, surgery centers, and vet
clinics throughout most of the United States.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
that express plans, anticipation, intent, contingencies, goals,
targets or future development and/or otherwise are not statements
of historical fact. These statements relate to future events or
future results of operations, including, but not limited to the
following statements: the company’s beliefs concerning the
commercialization of SYMJEPI and its other products and product
candidates; the extent of sales of SYMJEPI resulting from the
availability of the products within the Walgreens Prescription
Savings Club program; and the company's beliefs concerning the
ability of its product to compete successfully in the market; the
company's beliefs concerning the safety and effectiveness of
SYMJEPI or its other products and product candidates. These
statements are only predictions and involve known and unknown
risks, uncertainties and other factors, which may cause Adamis'
actual results to be materially different from these
forward-looking statements. You should not place undue reliance on
any forward-looking statements. There are no assurances regarding
the extent of sales of SYMJEPI products, or revenues to the
company, resulting from the availability of the products within the
Walgreens Prescription Savings Club program. Further, any
forward-looking statement speaks only as of the date on which it is
made, and except as may be required by applicable law, we undertake
no obligation to update or release publicly the results of any
revisions to these forward-looking statements or to reflect events
or circumstances arising after the date of this press release.
Certain of these risks, uncertainties, and other factors are
described in greater detail in Adamis’ filings from time to time
with the SEC, which Adamis strongly urges you to read and
consider, all of which are available free of charge on
the SEC's web site at http://www.sec.gov. Except to
the extent required by law, any forward-looking statements in this
press release speak only as the date of this press release, and
Adamis expressly disclaims any obligation to update any
forward-looking statements.
Contacts:
Mark FlatherSenior Director, Investor
Relations& Corporate CommunicationsAdamis Pharmaceuticals
Corporation(858) 412-7951mflather@adamispharma.com
______________________________
1 ProspectoRx data for epinephrine devices,
December 2020.
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024